Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)
EPIC (CCR100136) study team, Jan Gerstoft (Medlem af forfattergruppering)
15Citationer
(Scopus)
Fingeraftryk
Dyk ned i forskningsemnerne om 'Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)'. Sammen danner de et unikt fingeraftryk.